PX-3
PX-3 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.
The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1, PX-2 and APP-FUBINACA were reported by the EMCDDA in late 2014.Legality
Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.
